Brief: Shanghai Bio-heart Biological Technology Posts H1 Capex Of RMB19.8 Mln
Aug 19 (Reuters) - Shanghai Bio-heart Biological Technology H1 capex RMB 19.8 million. * H1 EPS RMB -0.11 * H1 net income RMB -28.3 million
Recent news on Shanghai Bio-heart Biological Technology
See all newsBrief: Shanghai Bio-Heart Biological Technology Says NMPA Approves Bioheart Bioabsorbable Drug-Eluting Stents
Brief: Shanghai Bio-Heart Biological Technology Says Iberis Rdn System Completes Registration In Vietnam
Brief: Shanghai Bio-Heart Biological Technology Says Iberis RDN System Completed Registration In Thailand
Brief: Shanghai Bio-Heart Biological Technology Says Iberis RDN System Completes Registration With MHRA In UK
Brief: Shanghai Bio-Heart Biological Technology's Controlling Shareholder Increases Shareholding